《新股消息》和铂医药-B(02142.HK)下周一起招股 入场费约13,050元
和铂医药-B(02142.HK)公布招股详情,将於下周一(30日)起至下周四(12月3日)招股,计划发行约1.38亿股,当中10%为本地公开发售,其余90%为国际配售,设15%超额配股权。招股价介乎每股11.7至12.92元,集资最多逾17.85亿元,每手1,000股入场费约13,050.19元,预期12月10日挂牌上市,由摩根士丹利、美国银行及中信证券担任联席保荐人。
是次招股将引入9个基石投资者,合共认购约9,200万美元等值股份,其中Black Rock Funds投资3,000万美元,HBM Health、高瓴资本、Hudson Bay Capital及Octagon Investments各投资1,000万美元,安澜资本投资700万美元,以及3W、奥博资本与君联资本分别认购500万美元等值股份。
以招股价中位数每股12.31元计,所得款项净额约为15.89亿元,约37%将用於研发核心产品HBM9161及HBM9036;约23%用於开发支柱资产HBM4003、注册备案及潜在商业化;约15%用於其他候选药物的研发;约12%用於和铂抗体平台产生的创新型分子发现及合作项目;约5%用以改进平台技术;余下约8%为一般营运资金。
首席商务官廖迈菁表示,公司目前主要委托CMO生产旗下的产品,中长期会积极考虑在中国建设生物制剂生产设施,届时将考虑产品需求、地方政府支持政策等去选址,未有透露时间表及预期投资规模。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.